Lexeo Therapeutics Stock Discussion

$Lexeo Therapeutics (LXEO.US)$
Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

$Lexeo Therapeutics (LXEO.US)$
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study
Monday, 7th April at 6:00 am
Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner
Clinically meaningful improvements in majority of participants across cardiac biomarkers and functional measures
All SUNRISE-FA participants achieved...

$Lexeo Therapeutics (LXEO.US)$
Breakthrough Data: Gene Therapy Shows 25% Heart Improvement in Fatal Rare Disease

$Lexeo Therapeutics (LXEO.US)$ 🤔

$Lexeo Therapeutics (LXEO.US)$
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints
Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling...

$Lexeo Therapeutics (LXEO.US)$
NEWS
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy